Back to Search
Start Over
An introduction to the Marburg virus vaccine consortium, MARVAC.
- Source :
-
PLoS pathogens [PLoS Pathog] 2022 Oct 13; Vol. 18 (10), pp. e1010805. Date of Electronic Publication: 2022 Oct 13 (Print Publication: 2022). - Publication Year :
- 2022
-
Abstract
- The emergence of Marburg virus (MARV) in Guinea and Ghana triggered the assembly of the MARV vaccine "MARVAC" consortium representing leaders in the field of vaccine research and development aiming to facilitate a rapid response to this infectious disease threat. Here, we discuss current progress, challenges, and future directions for MARV vaccines.<br />Competing Interests: T.W.G. holds U.S. patent number 7,635,485 issued to US Government, U.S. patent number 7,838,658 issued to Arbutus Biopharma, U.S. patent number 8,017,130 issued to US Government, U.S. patent number 8,716,464 issued to Arbutus Biopharma, and U.S. patent number 8,796,013 issued to Boston University. N.J.S. has a patent for Chimpanzee Adenoviral vector-based filovirus vaccines (for use in humans) with royalties paid to GlaxoSmithKline Biologicals. K.L.W. is a stockholder of Emergent BioSolutions. R.Z. holds a patent for “Methods and compositions for inducing protective immunity against Marburg virus infection”. All other authors declare no conflict of interest. The conclusions in this report are those of the authors and do not necessarily represent the official position of the U.S. Centers for Disease Control and Prevention.
Details
- Language :
- English
- ISSN :
- 1553-7374
- Volume :
- 18
- Issue :
- 10
- Database :
- MEDLINE
- Journal :
- PLoS pathogens
- Publication Type :
- Academic Journal
- Accession number :
- 36227853
- Full Text :
- https://doi.org/10.1371/journal.ppat.1010805